Keytruda vs. Tecentriq
Are Keytruda and Tecentriq the Same Thing?
Keytruda (pembrolizumab) and Tecentriq (atezolizumab) are monoclonal antibodies used to treat different types of cancer.
Keytruda is used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
Tecentriq is used to treat patients with locally advanced or metastatic urothelial carcinoma (cancer) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
Side effects of Keytruda and Tecentriq that are similar include fatigue, cough, shortness of breath, nausea, itching, rash, decreased appetite, constipation, joint pain, back or neck pain, and diarrhea.
Side effects of Keytruda that are different from Tecentriq include loss of skin pigmentation (vitiligo) and headache.
Side effects of Tecentriq that are different from Keytruda include vomiting, abdominal pain, urinary tract infection (UTI), fever, swelling of extremities, anemia, dehydration, intestinal obstruction, urinary obstruction, blood in the urine, acute kidney injury, venous thromboembolism, severe infection (sepsis), and pneumonia.
Both Keytruda and Tecentriq may interact with other drugs.
What Are Possible Side Effects of Keytruda?
Common side effects of Keytruda include:
Side effects of Keytruda include:
- fatigue,
- cough,
- shortness of breath,
- nausea,
- itching,
- rash,
- loss of skin pigmentation (vitiligo),
- decreased appetite,
- headache,
- constipation,
- joint pain,
- back pain, and
- diarrhea.
What Are Possible Side Effects of Tecentriq?
Common side effects of Tecentriq include:
- fatigue
- decreased appetite
- nausea
- vomiting
- constipation
- diarrhea
- abdominal pain
- urinary tract infection
- fever
- swelling of the extremities
- back or neck pain
- joint pain
- anemia
- dehydration
- itching
- rash
- intestinal obstruction
- urinary obstruction
- blood in the urine (hematuria)
- shortness of breath
- cough
- acute kidney injury
- venous thromboembolism
- severe infection (sepsis)
- pneumonia
What Is Keytruda?
Keytruda (pembrolizumab) is a monoclonal antibody used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
What Is Tecentriq?
Tecentriq (atezolizumab) Injection for intravenous infusion is a monoclonal antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (cancer) who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
What Drugs Interact With Keytruda?
Keytruda may interact with other drugs. Tell your doctor all medications and supplements you use. Keytruda is not recommended for use during pregnancy; it may harm a fetus. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding.
What Drugs Interact With Tecentriq?
Tecentriq may interact with other drugs. Tell your doctor all medications and supplements you use.
How Should Keytruda be Taken?
The recommended dose of Keytruda is 2 mg/kg administered as an intravenous infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
How Should Tecentriq be Taken?
The recommended dose of Tecentriq is 1200 mg administered as an intravenous infusion over 60 minutes every 3 weeks until disease progression or unacceptable toxicity.